| Summary: | Endriyas Kelta Wabalo, Abebe Dukessa Dubiwak, Mengistu Welde Senbetu, Tariku Sime Gizaw Department of Biomedical Sciences, Faculty of Medical Sciences, Institute of Health, Jimma University, Jimma, EthiopiaCorrespondence: Endriyas Kelta WabaloDepartment of Biomedical Sciences, Faculty of Medical Sciences, Institute of Health, Jimma University, Jimma, EthiopiaEmail keltatona@gmail.comAbstract: The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It is one of the RNA coronaviruses which share the highest mutation rates of RNA viruses when compared with that of their hosts. The collective mutation rate of RNA viruses is up to a million times higher than their hosts and is correlated with enhanced virulence of viruses. The RNA, genomic material of SARS-CoV-2, has the capacity of showing amplified fast changes as the infection spreads. These changes were frequently observed in genes for spike glycoprotein, nucleocapsid, ORF1ab, and ORF8, together with RNA dependent RNA polymerase. In contrast, genes for envelope, membrane, ORF6, ORF7a and ORF7b showed no observable changes in terms of amino acid substitutions. Mutated SARS COV-2 at these particular sites has been associated with viral infectivity, false laboratory results and viral genome mutation and interferes with therapeutic targets. Interferences with therapeutic targets is frequently observed in genes for RdRp. Additionally, mutated viral genes for RdRp render slow fidelity of RdRp protein, resulting in a high mutation rate. Such a high mutation rate might allow new virulent forms of the virus to emerge and influence the disease profile. This review aimed to elaborate on the effect of genomic and amino acid sequence mutations on the virulence and therapeutic targets of SARS COV-2. To achieve this objective, multiple literatures have been reviewed.Keywords: genomic mutations, amino acid sequence mutations, virulence, therapeutic target, RdRp, SARS COV-2, spike proteins
|
|---|
